Home

The Lab of Retinal Cell Biology belongs to the Dept. of Ophthalmology, University Eye Hospital Zurich. Head of Department: Prof. Dr. Dr. Daniel Barthelmes

 

 

Group picture
Group picture


Although many patients worldwide suffer from aquired or inherited retinal degenerations, successful therapies are still highly needed for the treatment of blinding diseases like age related macular degeneration (AMD) or Retinitis Pigmentosa (RP). The diversity of the stimuli (endogenous and exogenous) and the heterogeneity of phenotypes makes the design of treatment strategies difficult. The main reason for the lack of effective therapies, however, may be our incomplete understanding of the molecular events leading to retinal cell death and hence to the impairment of vision.

Our work focuses on the elucidation of the biochemical events and molecular signaling cascades that lead to retinal degeneration and execute cell death. The goal is to understand the pathways induced by the diverse stimuli and to develop gene therapy and neuroprotection based strategies that may ultimately lead to the rescue of vision in patients.

 

RBC Fluorescein
RBC Fluorescein
Retinal blood vessels visualized with fluorescein. Courtesy of Eva Kiessling.
RPE Phallaodin and DAPI
RPE Phallaodin and DAPI
RPE whole mount, stained for phallaodin (green) and DAPI (blue). Some cell nuclei are positive for a fluorescent marker (magenta). Courtesy of Lynn Ebner.
iRPE ZO-1 and FITC POS
iRPE ZO-1 and FITC POS
Induced human RPE cells (iRPE) stained for ZO-1 (red) and fed with FITC-labeled POS (green). Courtesy of Florian Peters.